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RESEARCH ARTICLE
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Abstract
Immunosuppressive agents are used for the treatment of immune-mediated myocarditis;
however, the need to develop a more effective therapeutic approach remains. Nano-sized
liposomes may accumulate in and selectively deliver drugs to an inflammatory lesion with
enhanced vascular permeability. The aims of this study were to investigate the distribution
of liposomal FK506, an immunosuppressive drug encapsulated within liposomes, and the
drug’s effects on cardiac function in a rat experimental autoimmune myocarditis (EAM)
model. We prepared polyethylene glycol-modified liposomal FK506 (mean diameter: 109.5
± 4.4 nm). We induced EAM by immunization with porcine myosin and assessed the tissue
distribution of the nano-sized beads and liposomal FK506 in this model. After liposomal or
free FK506 was administered on days 14 and 17 after immunization, the cytokine expres-
sion in the rat hearts along with the histological findings and hemodynamic parameters
were determined on day 21. Ex vivo fluorescent imaging revealed that intravenously admin-
istered fluorescent-labeled nano-sized beads had accumulated in myocarditic but not nor-
mal hearts on day 14 after immunization and thereafter. Compared to the administration of
free FK506, FK506 levels were increased in both the plasma and hearts of EAM rats when
liposomal FK506 was administered. The administration of liposomal FK506 markedly sup-
pressed the expression of cytokines, such as interferon-γ and tumor necrosis factor-α, and
reduced inflammation and fibrosis in the myocardium on day 21 compared to free FK506.
The administration of liposomal FK506 also markedly ameliorated cardiac dysfunction on
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day 21 compared to free FK506. Nano-sized liposomes may be a promising drug delivery
system for targeting myocarditic hearts with cardioprotective agents.
Introduction
Myocarditis is defined as an inflammatory disease of the myocardium caused by viral or bacte-
rial infection, drugs, or autoimmune diseases [1]. Histological analysis shows the inflammatory
infiltration of leukocytes within the myocardium [1,2]. Cytokines produced by leukocytes,
such as T-lymphocytes and macrophages, play a crucial role in the pathogenesis of myocardial
damage in myocarditis [1,3]. In the acute phase of myocarditis, the cytokines released from the
T helper-1 (Th1) and T helper-17 (Th17) lymphocyte subsets are elevated in the myocardium
[4,5]. Although immunosuppressive agents are believed to improve the survival of patients
with immune-mediated myocarditis [6,7], the prognosis of some immune-mediated myocardi-
tis, such as giant cell myocarditis (GCM), remains poor, and a more effective therapy must be
developed [1].
Liposomes are nano-sized particles that are widely used for drug delivery to target specific
organs with enhanced vascular permeability due to inflammation [8,9,10]. We have demon-
strated that the targeted delivery of drugs to the ischemic/reperfused myocardium with lipo-
somes has a promising therapeutic implication for cardiovascular diseases [11,12]. Because
enhanced vascular permeability may occur in myocarditic hearts due to severe inflammation,
we hypothesized that encapsulating an immunosuppressive agent within liposomes would
increase its therapeutic effects.
FK506 is an immunosuppressive agent that suppresses T-cell activation by inhibiting calci-
neurin and decreases the level of interleukin (IL)-2 that triggers the release of cytokines from
Th1 and Th17 lymphocytes [13]. We thus encapsulated FK506 in liposomes and examined the
targeted accumulation of liposomal FK506 in experimental autoimmune myocarditis (EAM)
rat hearts [14,15]. Additionally, we compared the effects of liposomal FK506 and free FK506
on the expression of cytokines along with the histological findings in the heart and hemody-
namic parameters in EAM rats. This EAMmodel is characterized by the infiltration of T-lym-
phocytes and the appearance of multinucleated giant cells in the myocardium, and has been
used as a disease model for GCM [16].
Materials and Methods
Materials
To prepare the liposomes, 1,2-dipalmitoyl-sn-glycero- 3-phosphocholine (DPPC), cholesterol,
and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine -N-poly(ethylene glycol) 2000 (DSPE-
PEG) were obtained from Nippon Fine Chemical Co. (Takasago, Hyogo, Japan). FK506 was
provided by Astellas Pharmaceutical Co., Ltd. (Tokyo, Japan). [3H]-FK506 was obtained from
American Radiolabeled Chemicals, Inc. (St. Louis, MO, USA). All other materials were
obtained from Sigma-Aldrich (St. Louis, MO, USA).
Preparation of liposomal FK506
The lipid composition of liposomal FK506 was DPPC and DSPE-PEG in a 20:1 molar ratio.
Liposomal FK506 was prepared as previously reported [14]. The particle size and zeta potential
of liposomal FK506 were characterized by a dynamic light scattering analysis (Zetasizer Nano
Liposomal FK506 in Myocarditis
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ZS; Malvern, Worcestershire, UK). The analyses were performed 15 times per sample, and the
results represented the analysis of 3 independent experiments.
Preparation of rat EAMmodel
Porcine cardiac myosin was prepared as previously reported [15]. Male Lewis rats (7 weeks old
and weighing 190–220 g; Japan SLC, Inc., Shizuoka, Japan) received a single immunization in
the footpads with a myosin-adjuvant emulsion according to the procedure described previously
[17].
All animal experiments were performed in compliance with the guidelines of the Institute of
Experimental Animal Sciences of the Osaka University Graduate School of Medicine. All rats
were allowed ad libitum access to standard rodent chow and water, and housed in plastic cages
maintained in a facility with a temperature of 23 ± 1.5°C and a 12 hr light/dark cycle. The pro-
tocol was approved by the Animal Care and Use Committee of the Osaka University Graduate
School of Medicine (Approval number: 25-117-002) and all efforts were made to minimize suf-
fering. Rats were euthanized by intraperitoneal injection with an overdose of pentobarbital
(100 mg/kg), after measurement of hemodynamic parameters or before excision of hearts and
other organs. The rats were monitored every day during the experimental procedure. Rats with
weight loss20% of the initial weight were scheduled to be euthanized, but no rat in this study
met the requirement for early euthanasia. There was no rat died prior to the experimental
endpoint.
Immunohistological analysis
The immunohistological analysis was performed as described previously [18]. Sections were
used for hematoxylin and eosin (HE) and Masson’s trichrome (MTC) staining and were exam-
ined by microscopy (BZ-9000, KEYENCE, Tokyo, Japan). The area percentages of cell infiltra-
tion and of fibrosis were calculated using Image J (NIH Freeware) [19].
Experimental protocols
A. Time-course changes in vascular permeability in myocarditic hearts. On day 0, the
rats received a single immunization to induce myocarditis. We examined the time-course
changes in the vascular permeability in the myocarditic hearts of the EAMmodel rats on days
0, 10, 14, 17 and 21 after immunization. The rats were anesthetized with intraperitoneal
sodium pentobarbital (50 mg/kg) and butorphanol (2.5 mg/kg). The fluorescent dye-labeled
beads used in this study was carboxylate-modified beads with the diameter of 100 nm. These
beads were labeled with red fluorescent (580/605; absorption/emission wavelength in nm,
FluoSpheres F8801, Invitrogen, Carlsbad, CA, USA). The beads were dissolved in saline
(500 μL/rat, 20% vol/vol) and were intravenously administered to the rats. Five minutes later,
ex vivo fluorescence images were obtained using an Olympus SZX12 stereoscopic microscope
equipped with a DP71 digital camera (Olympus, Tokyo, Japan).
B. Tissue distribution of liposomal FK506. To examine the tissue distribution of FK506,
EAM rats on day 17 after immunization were anesthetized and received a single administration
of liposomal [3H]-FK506 or free [3H]-FK506 via the jugular vein. Each rat received 0.01 mg of
FK506 in a mixture of nonisotopic and [3H]-labeled FK506 at a 30:1 ratio (74 kBq/500 μL/rat).
Two hours after administration, the rats were sacrificed for the collection of blood, heart, lung,
liver and kidney specimens.
C. Effects of free or liposomal FK506 on heart inflammation and hemodynamic parame-
ters. To examine the effects of free FK506, the rats received a single administration of 3 doses
of free FK506 (0.035, 0.17 or 0.35 mg/kg) via the tail vein on days 14 and 17 after immunization.
Liposomal FK506 in Myocarditis
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To examine the effect of liposomal FK506, a corresponding dose of free or liposomal FK506
(0.035 mg/kg and 0.17 mg/kg) was administered. On day 21 after immunization, the hearts
were excised and the cytokine expressions in the myocarditic hearts were evaluated. In another
series of experiments, the histological analysis and hemodynamic parameters were also analyzed
on day 21 after immunization.
Invasive measurement of hemodynamics
A 2-Fr Millar Mikro-tip catheter (SPR-320, Millar Instruments, Houston, TX, USA) was
inserted via the right carotid artery and carefully introduced into the left ventricle. We
obtained the hemodynamic parameters, such as heart rate (HR), left ventricular systolic pres-
sure (LVSP), left ventricular end-diastolic pressure (LVEDP), and the maximum and mini-
mum rates of left ventricular pressure (max dP/dt and min dP/dt). These parameters were
analyzed using an application program Blood Pressure Module (LabChart, ADInstruments,
Castle Hill, Australia).
Measurement of [3H] radioactivity
The plasma and organ samples were obtained and the radioactivity was measured as previously
reported [11]. The results were expressed as a percentage of the administered dose per 1 ml of
plasma or 1 g of wet tissue weight.
Real-time quantitative polymerase chain reaction
We obtained samples after the drug treatment and prepared them according to the Omniscript
Reverse Transcription Handbook (QIAGEN Inc., Hilden, Germany). The rat primers used for
the quantification of cytokines, including interferon-γ (IFN-γ), interleukin-17 (IL-17), tumor
necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-10 (IL-10), interleukin-4 (IL-4)
and transforming growth factor-β (TGF-β), and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) were all designed according to the manufacturer’s protocol (Applied Biosystems,
Foster City, CA, USA; https://www.appliedbiosystems.com/). Real-time quantitative PCR was
performed as described previously [18]. The primer sequences were as follows: IFN-γ, 5’-
ctctctggctgttactgc-3’ (sense) and 5’-ccttttgccagttcctcc-3’ (antisense);
IL-17, 5’-ttccacttcaccctggactc-3’ (sense) and 5’-tcccctcagcgttgacac-3’
(antisense); TNF-α, 5’-cccaacaaggaggagaag-3’ (sense) and 5’-tggtggtttgcta
cgacg-3’ (antisense); IL-1β, 5’-tgtgatgaaagacggcacac-3’ (sense) and 5’-ctt
cttctttgggtattgtttgg-3’ (antisense); IL-10, 5’-agtggagcaggtgaagaatga-3’
(sense) and 5’-tcatggccttgtagacacctt-3’ (antisense); IL-4, 5'-tgatgtacctccg
tgcttga-3' (sense) and 5’-gtgagttcagaccgctgaca-3’ (antisense); TGF-β, 5’-
gcaacacgtagaactctaccagaa-3’ (sense) and 5’-cagccactcaggcgtatca-3’
(antisense); GAPDH, 5’-tcaacggcacagtcaagg-3’ (sense) and 5’-cacgacatact
cagcacc-3’ (antisense).
Statistical analysis
One-way ANOVA followed by Tukey's statistics were used to determine the differences in the
hemodynamic parameters, mRNA expression levels and histological findings among the groups.
To compare the tissue distributions and hemodynamic parameters between the groups treated
with free and liposomal FK506, unpaired t-tests were performed. The data are expressed as the
mean ± SEM. In all analyses, P< 0.05 was considered to be statistically significant.
Liposomal FK506 in Myocarditis
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Results
Effects of free FK506 on hemodynamic parameters in the rat EAMmodel
We tested the dose-dependent effects of free FK506 on the hemodynamic parameters on day
21 after immunization in the EAM rats. Free FK506 at the doses of 0.17 and 0.35 mg/kg, but
not 0.035 mg/kg, improved the hemodynamic parameters, such as LVSP, LVEDP and dP/dt,
on day 21 to the same extent (Fig 1). The HR in the normal rat group (417.1 ± 9.9 beats/min)
did not differ from the other groups tested (Saline group: 368.4 ± 20.5 beats/min; FK506 0.035
mg/kg group: 364.5 ± 11.0 beats/min; FK506 0.17 mg/kg group: 389.2 ± 9.7 beats/min; FK506
0.35 mg/kg group: 390.8 ± 21.6 beats/min).
Time-course changes in cardiac vascular permeability in the rat EAM
model
We assessed the time-course changes in the cardiac vascular permeability in the rat EAM
model using nano-sized fluorescent beads (100 nm). An ex vivo fluorescent image analysis
showed that an accumulation of nano-sized fluorescent beads was found in the hearts on day
14 after immunization and thereafter (Fig 2).
Preparation of liposomal FK506 and tissue distribution of free and
liposomal FK506 in the rat EAMmodel
We encapsulated FK506 into liposomes as previously reported [14]. The dynamic light scattering
analysis showed that the particle size and zeta potential of the FK506 liposomes were 109.5±4.4
nm and -7.2±0.7 mV, respectively.
The plasma levels of [3H]-FK506 in the rats treated with liposomal FK506 were significantly
higher than those treated with free FK506. The accumulation of radioisotopes in the heart, but
not in the lung, liver, or kidney, was also significantly higher when rats received liposomal
FK506 compared to free FK506 (Fig 3).
Effects of free and liposomal FK506 on cytokine expression and
histological findings in the rat EAMmodel
Next, we examined the effects of free and liposomal FK506 on cytokine expression and histo-
logical findings in the rat EAMmodel. Because free FK506 at 0.17mg/kg and 0.35 mg/kg
improved cardiac function of EAM rats to the same extent (Fig 1), we used an insufficient dose
of free FK506 at 0.035 mg/kg to compare the therapeutic effects between free and liposomal
FK506 on EAM. We examined the effects of free and liposomal FK506 on the mRNA expres-
sion of Th1 cytokine (IFN-γ), Th17 cytokine (IL-17) and proinflammatory cytokines (TNF-α
and IL-1β) in rat myocarditic hearts on day 21 after immunization. Compared to the cytokine
expression in myocarditic hearts treated with saline, liposomal FK506, but not free FK506, sig-
nificantly decreased the expression of IFN-γ and TNF-α (Fig 4A and 4C). The expression of
IL-17 and IL-1β were significantly decreased by both free and liposomal FK506 (Fig 4B and
4D). Because IL-10 was reported to have a therapeutic effect against autoimmune myocarditis
[20], we investigated the expression of IL-10 in the hearts of EAM rats. IL-10 expression did
not increase in EAM rats compared to normal rats on day 21. Furthermore, free or liposomal
FK506 did not change the expression of IL-10 (Fig 4E).
Because Th2 cytokines have anti-inflammatory effects on this rat EAMmodel [21], we
examined the expression of Th2 (IL-4) and found that liposomal, but not free FK506, signifi-
cantly increased the expression of IL-4 (Fig 4F). Compared to saline, liposomal FK506, but not
Liposomal FK506 in Myocarditis
PLOS ONE | DOI:10.1371/journal.pone.0160944 August 8, 2016 5 / 14
free FK506, significantly decreased the expression of TGF-β that induces fibrosis in this EAM
model [22] (Fig 4G).
We also examined the effects of free and liposomal FK506 on the histological findings at the
dose of 0.035 mg/kg. Compared to saline, liposomal FK506, but not free FK506, significantly
reduced the areas of cell infiltration and fibrosis in the myocarditic hearts. Moreover, liposomal
FK506 significantly reduced the areas of cell infiltration and fibrosis than free FK506 in the
myocarditic hearts (Fig 5A, 5B and 5C).
Fig 1. Effects of free FK506 on hemodynamic parameters in the rat EAMmodel.Quantitative data of
hemodynamic parameters, including left ventricular systolic pressure (LVSP), left ventricular end-diastolic
pressure (LVEDP), max dP/dt and minimum dP/dt, on day 21 after immunization. Drugs were intravenously
administered on days 14 and 17 after immunization. Rats were divided into Normal, EAMwith saline
treatment and EAMwith free FK506 (0.035, 0.17 or 0.35 mg/kg) treatment groups (N = 5–15 in each group).
Data are expressed as the mean ± SEM. * P < 0.05 versus the saline treated group.
doi:10.1371/journal.pone.0160944.g001
Fig 2. Time-course changes in vascular permeability in myocarditic hearts in the rat EAMmodel. The
representative brightfield and fluorescent images of the myocarditic hearts of rats that received fluorescent-
labeled nano-sized beads (100 nm) are shown in the upper and lower panels, respectively. Hearts were
excised on days 0, 10, 14, 17 and 21 after immunization. In each time point, 2–3 rats were checked. Bar
indicates 10 mm.
doi:10.1371/journal.pone.0160944.g002
Liposomal FK506 in Myocarditis
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To investigate whether a higher dose of FK506 has more therapeutic effect on EAM than
that of 0.035 mg/kg, we compared the histological findings between free and liposomal FK506
at the dose of 0.17 mg/kg. We found that both free and liposomal FK506 at the dose of 0.17
mg/kg reduced the areas of cell infiltration (free FK506: 28.52 ± 0.87%, n = 4, liposomal FK506:
26.96 ± 2.66%, n = 3 vs. saline: 42.39 ± 3.00%, n = 4) and fibrosis (free FK506: 42.28 ± 1.51%,
n = 4, liposomal FK506: 38.83 ± 1.58%, n = 3 vs. saline: 51.00 ± 1.39%, n = 4) in the myocarditic
Fig 3. Tissue distribution of free and liposomal FK506 in the rat EAMmodel. Tissue distributions of [3H]-
labeled FK506 in the rat EAMmodel. Radioisotope activity in tissues was measured 2 hours after the single
intravenous administration of free or liposomal [3H]-labeled FK506 on day 17 after immunization (N = 4 in
each group). Data are expressed as the mean ± SEM. * P < 0.05 versus the free FK506 treated group.
doi:10.1371/journal.pone.0160944.g003
Fig 4. Effects of free and liposomal FK506 on inflammatory cytokines in the hearts of EAM rats.
Cytokine expression on day 21 after immunization was evaluated using real-time quantitative PCR. Relative
expression of IFN-γ (A), IL-17 (B), TNF-α (C), IL-1β (D), IL-10 (E), IL-4 (F) and TGF-β (G) were normalized to
GAPDH (N = 4–9 in each group). Data are expressed as the mean ± SEM. * P < 0.05 versus the saline
treated group.
doi:10.1371/journal.pone.0160944.g004
Liposomal FK506 in Myocarditis
PLOS ONE | DOI:10.1371/journal.pone.0160944 August 8, 2016 7 / 14
hearts. These reductions to the saline treated group in the areas of cell infiltration (free FK506:
32.71%, liposomal FK506: 36.40%) and fibrosis (free FK506: 15.1%, liposomal FK506: 22.03%)
by free and liposomal FK506 at 0.17 mg/kg were comparable with those by liposomal FK506 at
0.035 mg/kg (30.47% in the area of cell infiltration, 22.35% in the area of fibrosis). However,
there was no significant difference in the anti-inflammatory effect between free and liposomal
FK506 groups at the dose of 0.17mg/kg.
Liposomal FK506 efficiently improved cardiac dysfunction in the rat EAM
model
Next, we evaluated the effects of free and liposomal FK506 (0.035 mg/kg) on the hemodynamic
parameters. Compared to free FK506, liposomal FK506 significantly improved the hemody-
namic parameters, such as LVEDP and dP/dt, on day 21 after immunization (Fig 6).
We also compared the hemodynamic parameters between free and liposomal FK506 at the
dose of 0.17 mg/kg. There was no significant difference in the therapeutic effect on hemody-
namic parameters, including LVSP (free FK506: 102.7 ± 11.2 mmHg, n = 3 vs. liposomal
FK506: 103.2 ± 7.0 mmHg, n = 4), LVEDP (free FK506: 6.3 ± 1.3 mmHg vs. liposomal FK506:
7.0 ± 0.4 mmHg), max dP/dt (free FK506: 5971.6 ± 1029.3 mmHg/s vs. liposomal FK506:
5681.7 ± 902.8 mmHg/s) and minimum dP/dt (free FK506: -5256.7 ± 821.6 mmHg vs. lipo-
somal FK506: -5255.1 ± 701.5 mmHg/s) between free and liposomal FK506 groups.
Fig 5. Effects of free and liposomal FK506 on histological findings in the myocarditic hearts.
Representative transverse sections in ventricles stained with hematoxylin and eosin (upper panels) and
Masson’s trichrome (lower panels) at low magnification (A) and high magnification (C). (B) Quantitative
analysis of areas of cell infiltration and fibrosis (N = 4–12 in each group). Scale bars indicate 5mm and
500 μm in (A) and (C), respectively. Data are expressed as the mean ± SEM. * P < 0.05 versus the saline
treated group. # P < 0.05 versus the free FK506 treated group.
doi:10.1371/journal.pone.0160944.g005
Liposomal FK506 in Myocarditis
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Discussion
In the present study, we demonstrated that nano-sized liposomes specifically accumulated in
myocarditic hearts. Experiments with [3H]-labeled FK506 revealed that the plasma and heart
tissue levels of FK506 in EAM rats were significantly higher when liposomal FK506 was intra-
venously administered compared to free FK506. Consistently, compared to free FK506 at the
dose of 0.035 mg/kg, corresponding dose of liposomal FK506 suppressed cytokine expression
in the hearts and improved the histological findings and cardiac function in EAM rats.
Immunosuppressive therapy has favorable effects in chronic virus-negative myocarditis,
GCM and active myocarditis defined as autoimmune [2]. However, some patients with GCM
still require mechanical circulatory support or a heart transplantation within 1 year [1,6].
Therefore, the development of a more effective immunosuppressive therapy in the acute phase
of autoimmune myocarditis would meet a worldwide need.
Immunosuppressive therapy for immune-mediated myocarditis includes steroids alone,
azathioprine and steroids, or cyclosporine A [1]. FK506 and cyclosporine A are calcineurin
inhibitors, and they are used in clinical settings for patients received organ transplantation to
prevent allograft rejection [13]. We chose FK506 due to its stronger bioactivity compared to
cyclosporine A, which is suitable for encapsulation in liposomes [13]. Although the repetitive
intramuscular administration of FK506 before or after the onset of inflammation has the
potential to attenuate myocardial inflammation in the EAMmodel [23,24], the intravenous
administration of FK506 after the onset of inflammation in the myocardium would be more
applicable to a clinical setting. The initiation of myocardial inflammation occurs on days 11–
14, and the cardiac dysfunction peaks on approximately day 21 after immunization [19]. We
intravenously administered FK506 on days 14 and 17, which are periods after the onset of
Fig 6. Effects of free and liposomal FK506 on hemodynamic parameters in the rat EAMmodel.
Quantitative data of hemodynamic parameters including left ventricular systolic pressure (LVSP), left
ventricular end-diastolic pressure (LVEDP), max dP/dt and minimum dP/dt. EAM rats were treated with free
or liposomal FK506 (0.035 mg/kg) on days 14 and 17 after immunization (N = 6 and 9, respectively). Data are
expressed as the mean ± SEM. * P < 0.05 versus the free FK506 treated group.
doi:10.1371/journal.pone.0160944.g006
Liposomal FK506 in Myocarditis
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myocardial inflammation and before the peak of cardiac dysfunction. We chose 0.035 and 0.17
mg/kg of FK506, because 0.035 and 0.17 mg/kg/day are comparable with the insufficient and
minimum effective dose in a rat allograft model, respectively [25,26]. In addition, we also
examined the effect of a higher dose of 0.35mg/kg on hemodynamic parameters in EAM rats.
Free FK506 at 0.17mg/kg and 0.35 mg/kg improved cardiac function of EAM rats to the same
extent (Fig 1), indicating that free FK506 at 0.17 mg/kg attained a maximum therapeutic effi-
cacy in rat EAMmodel. Therefore, we chose the submaximal dose of FK506 (0.035 mg/kg) to
investigate whether liposomal formulation of FK506 can enhance the therapeutic efficacy of
FK506.
Vascular permeability is often enhanced in tissues and organs in which inflammation is
induced [8]. Nano-sized particles can pass through the vascular walls and accumulate in the
interstitial tissues in which vascular permeability is enhanced [8]. Therefore, nano-sized parti-
cles such as liposomes are considered to be an ideal material to deliver drugs efficiently to
inflamed tissues and organs such as those involved by cancer, infection and ischemia/reperfu-
sion [8,9,10]. We have demonstrated that encapsulating drugs in liposomes augments their
pharmaceutical effects in an ischemia/reperfusion rat model [11,12,27]. In the present study,
along with the progression of myocardial inflammation, we found that nano-sized beads accu-
mulated in the hearts of the EAMmodel rats (Fig 2). This finding indicates that nano-sized
liposomes may be a promising drug delivery system for targeting myocarditic hearts with car-
dioprotective agents. Moffatt SD, et al. reported that a liposomal FK506 was efficacious in spite
of low blood trough concentration of FK506, which brings the benefit for clinical organ trans-
plantation [28]. They prepared the liposomal FK506 through 220 nm filters and obtained the
liposomal FK506 which diameter was less than 220 nm. However, the peak and distribution of
liposome diameter were not determined. On the other hand, we clearly characterized the lipo-
somal FK506 which peak and distribution was 109.5±4.4 nm. Importantly, comparing to the
liposome used in the previous study, our liposome was PEG-modified, which can potentially
reduce uptake by phagocytic cells and enable liposome to remain in the blood circulation for
long term [29]. Consistently, the FK506 level was significantly higher in the plasma in EAM
rats treated with PEG-modified liposomal FK506, compared to that in EAM rats treated with
free FK506 (Fig 3), suggesting that PEG-modification extended FK506 circulation time and
improved its therapeutic effect against myocarditis. The accumulation of [3H]-FK506 in the
whole heart was significantly increased (1.37-fold) in liposomal FK506 compared to free
FK506. Because myocarditic hearts have focal inflammatory lesions wherein vascular perme-
ability is enhanced, FK506 levels in the focal inflammatory lesions could be much higher for
the liposomal FK506 group.
Cytokines produced by leukocytes, such as T-lymphocytes and macrophages, play a crucial
role in the pathogenesis of myocardial damage in myocarditis [1,3]. To examine the immuno-
suppressive effects of liposomal FK506, we evaluated the mRNA expression of inflammatory
cytokines in the hearts of EAM rats. Th1 and Th17 lymphocytes play an important role in the
progression of immune-mediated myocarditis; therefore, we assessed the IFN-γ secreted from
Th1 lymphocytes, IL-17 secreted from Th17 lymphocytes, and TNF-α and IL-1β secreted from
macrophages [30,31,32]. Importantly, FK506 may suppress the function of T cells via calci-
neurin inhibition and may also directly suppress the production of a variety of T-cell-triggered
cytokines such as IFN-γ, IL-17, TNF-α and IL-1β in several autoimmune diseases [13,33]. In
this study, although we did not find statistically significant differences in each cytokine expres-
sion between free and liposomal FK506, liposomal FK506 significantly decreased the expres-
sion of 4 inflammatory cytokines (IFN-γ, IL-17, TNF-α, IL-1β) compared to saline, but free
FK506 only decreased 2 of them (IL-17 and IL-1β) (Fig 4A, 4B, 4C and 4D). These findings
suggested that liposomal FK506 may more efficiently suppress cytokine expression compared
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to free one. The combination of changes in cytokine expression by liposomal FK506 may syn-
ergistically contribute to the improvement of histological findings and hemodynamic changes
in EAM rats.
We also examined the expression of anti-inflammatory cytokine, IL-10, on day 21 (Fig 4E).
IL-10 expression did not increase in EAM rats compared to normal rats. Furthermore, free or
liposomal FK506 did not change the expression of IL-10, indicating that FK506 improved his-
tological findings and cardiac function independent of IL-10. Because IL-10 is reported to play
an important role in the recovery phase (24–30 days after immunization of porcine myosin),
the role of IL-10 is minimum in acute phase (day 21 after immunization) in the present study.
Moreover, Fuse K. et al. demonstrated that inflammatory Th1 cytokines (e.g. IFN-γ) sup-
press the expression of anti-inflammatory Th2 cytokines (e.g. IL-4) in the acute phase of EAM.
In the present study, we also investigated the expression of IL-4 in the acute phase (day 21),
because FK506 potentially suppresses the expression of Th1 cytokines, which may lead to
increased expression of IL-4 in acute phase. As shown in Fig 4F, the expression of IL-4 was sig-
nificantly increased in liposomal FK506 treated group, compared to that in saline treated
group. These results indicated that the decrease of IFN-γ and the increase of IL-4 by liposomal
FK506 in the hearts of EAM rats may contribute to the therapeutic effects of liposomal FK506
on EAM. In addition, we investigated the expression of TGF-β that was reported to induce
cardiac fibrosis [22]. As shown in Fig 4G, TGF-β expression in the hearts of EAM rats was
decreased by liposomal but not free FK506, comparing to that in the hearts of EAM rats treated
with saline. These findings suggest that liposomal FK506 inhibited cardiac fibrosis via TGF-β
signal pathway.
Next, we evaluated the therapeutic effects of liposomal FK506 on the histological findings in
the hearts of EAM rats. In autoimmune myocarditis, cytokines induce a large amount of inflam-
matory cell infiltration at an early phase and fibrotic changes at a later phase, which leads to tis-
sue atrophy and organ dysfunction [30]. Liposomal FK506 significantly reduced the areas of cell
infiltration and fibrosis than free FK506 in the myocarditic hearts (Fig 5A, 5B and 5C).
Moreover, we evaluated the therapeutic effects of liposomal FK506 on the hemodynamic
parameters. Compared to free FK506, liposomal FK506 significantly improved the hemody-
namic parameters (Fig 6). Cytotoxic T-lymphocytes and macrophages, both of which are trig-
gered by the activation of Th1 and/or Th17 lymphocytes, may directly damage cardiomyocytes
and may also induce cardiomyocyte apoptosis [34]. Cytokines such as TNF-α and IL-1β them-
selves produce negative inotropic effects on cardiomyocytes [34,35]. We have demonstrated
that liposomal FK506 significantly suppressed inflammatory cytokines, improved the histologi-
cal findings, such as the reduced areas of cell infiltration and fibrosis, and improved the cardiac
function.
We also challenged a higher dose of free or liposomal FK506 to investigate whether liposomal
FK506 still has more therapeutic effect on EAM. Both free and liposomal FK506 treatment
improved the histological findings to the same extent at the dose of 0.17 mg/kg, and the
improvement compared to saline treated group was comparable with those treated by liposomal
FK506 at 0.035 mg/kg. There was also no significant difference in hemodynamic parameters
between free and liposomal FK506 treatment at the dose of 0.17 mg/kg. These results indicated
that the therapeutic efficacy of free FK506 reached maximum level at the dose of 0.17mg/kg in
this EAM rat model, and the increased accumulation of FK506 could not improve the therapeu-
tic efficacy at the dose of 0.17 mg/kg. On the other hand, liposomal FK506 at the dose of 0.035
mg/kg was more effective than the free one in the treatment of EAM, which suggesting that the
mechanisms of the improvement of therapeutic effects of liposomal formulation of FK506 at the
submaximal dose (0.035 mg/kg) was due to the increased FK506 accumulation to the inflamma-
tory tissue targeted by liposomes.
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In conclusion, we observed that nano-sized particles specifically accumulated in myocarditic
hearts and the level of FK506 was increased by liposomal FK506 administration compared to
free FK506 administration. The increased accumulation of FK506 suppressed inflammatory
cytokine expression, inflammatory cell infiltration and cardiac fibrosis, and ameliorated car-
diac dysfunction, which suggested that liposomal FK506 treatment is an effective therapy for
acute autoimmune myocarditis. These results indicated that the liposome is an effective
method to enhance the therapeutic efficacy of FK506 in the acute phase of autoimmune
myocarditis.
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